Selective CDK7 Inhibition for Therapy-Resistant Estrogen Receptor–Positive Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Selective CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor positive breast cancer
Clin. Cancer Res 2024 Feb 21;[EPub Ahead of Print], C Guarducci, A Nardone, D Russo, Z Nagy, C Heraud, A Grinshpun, Q Zhang, A Freelander, MJ Leventhal, A Feit, G Cohen Feit, A Feiglin, W Liu, F Hermida-Prado, N Kesten, W Ma, C De Angelis, A Morlando, M O'Donnell, S Naumenko, S Huang, QD Nguyen, Y Huang, L Malorni, JS Bergholz Villafane, JJ Zhao, E Fraenkel, E Lim, R Schiff, GI Shapiro, R JeselsohnFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.